Answers are grounded in this paper and cite their sources.
OBJECTIVE: It remains unknown how to stratify the risk of clinical relapse of chronic hepatitis B (CHB) patients after stopping nucleos(t)ide analogs (NAs) antiviral therapy. METHODS: The current post hoc analysis included 122 non-cirrhotic patients with chronic hepatitis B virus infection who were positive for hepatitis B envelope antigen (HBeAg) and discontinued long-term NA therapy after achieving HBeAg seroconversion for a median of 2.5 years. Post hoc analysis of end-of-treatment (EOT) hepatitis B core-related antigen (HBcrAg) levels was performed using a chemiluminescent enzyme immunoassay. CONCLUSION: U/mL may identify patients at high risk of clinical relapse after treatment cessation.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: